{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T01:47:16Z","timestamp":1780537636658,"version":"3.54.1"},"reference-count":28,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2025,11,4]],"date-time":"2025-11-04T00:00:00Z","timestamp":1762214400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2025,11,4]],"date-time":"2025-11-04T00:00:00Z","timestamp":1762214400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["headachejournal.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Headache"],"published-print":{"date-parts":[[2026,3]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Objective\/Background<\/jats:title>\n                    <jats:p>This study was undertaken to assess participants' impression of use and satisfaction with STS101 in a long\u2010term, open\u2010label safety study. The ASCEND study assessed the safety and tolerability of STS101, an investigational drug\u2013device combination of 5.2\u2009mg dihydroergotamine in a single\u2010use nasal delivery device for the acute treatment of migraine with\/without aura, across 12\u2009months.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>ASCEND (NCT04406649) was an open\u2010label, single\u2010arm, prospective interventional study in adults (18\u201365\u2009years) with history of migraine from September 2020 to January 2023. Participants could self\u2010administer STS101 for \u22642 doses within 24\u2009h to treat a single migraine attack and \u226412 doses\/month. Data on patient global impression, ease\u2010of\u2010use impression, patient likelihood of use, and comparison of study medication with previously used migraine medication were collected at 3\u2010, 6\u2010, and 12\u2010month timepoints. Participants' ratings were assessed using a 5\u2010point Likert scale. Exploratory efficacy parameters (freedom from pain and most bothersome symptom) were recorded in participants' electronic diaries.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Overall, the majority of participants had favorable impressions of STS101, which were consistent across the assessments at 3\u2010, 6\u2010, and 12\u2010month timepoints. STS101 was considered easy or very easy to use by 92.3%, 92.9%, and 91.2% of participants at months 3, 6, and 12, respectively. After 3, 6, and 12\u2009months of use, 78.9%, 80.5%, and 73.7% of participants indicated they were likely or very likely to use STS101 if it was available. When asked at the 3\u2010, 6\u2010, and 12\u2010month assessments to compare STS101 to their usual migraine medication, 63.9%, 74.1%, and 70.1% of participants agreed or strongly agreed that STS101 helped them return to normal faster than their usual medication. A total of 64.9%, 66.1%, and 69.3% of participants agreed or strongly agreed that STS101 worked faster and 67.0%, 73.7%, and 72.5% of participants agreed or strongly agreed that STS101 worked more consistently than their usual medication. Treatment with STS101 showed freedom from headache pain at 2, 4, 24, and 48\u2009h postdose in 33.3%, 61.3%, 86.2%, and 91.1% of participants, respectively. Similar trends were seen in freedom from most bothersome symptom as reported by 53.3%, 78.0%, 91.9%, and 93.7% of participants at 2, 4, 24, and 48\u2009h postdose, respectively.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Participant impression data through 12\u2009months suggest that STS101 was generally perceived as favorable by participants on multiple attributes. Most considered STS101 easy to use and indicated they would be likely to use the product if it were available. Exploratory efficacy evaluations indicated beneficial effects.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/head.15086","type":"journal-article","created":{"date-parts":[[2025,11,4]],"date-time":"2025-11-04T19:04:26Z","timestamp":1762283066000},"page":"688-696","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Study participant impression of use and satisfaction with STS101 (dihydroergotamine nasal powder): Results from the open\u2010label ASCEND acute migraine study"],"prefix":"10.1111","volume":"66","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8106-4927","authenticated-orcid":false,"given":"Jessica","family":"Ailani","sequence":"first","affiliation":[{"name":"Department of Neurology Georgetown University  Washington DC USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7708-5394","authenticated-orcid":false,"suffix":"IV","given":"Larry","family":"Charleston","sequence":"additional","affiliation":[{"name":"Charleston Health Neurology &amp; Head Pain Consultants  Pinckney Michigan USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-2305-0604","authenticated-orcid":false,"given":"Shannon","family":"Strom","sequence":"additional","affiliation":[{"name":"Satsuma Pharmaceuticals, Inc.  Durham North Carolina USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-8702-8199","authenticated-orcid":false,"given":"Detlef","family":"Albrecht","sequence":"additional","affiliation":[{"name":"Satsuma Pharmaceuticals, Inc.  Durham North Carolina USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6868-0108","authenticated-orcid":false,"given":"Robert","family":"Cowan","sequence":"additional","affiliation":[{"name":"Department of Neurology and Neurological Sciences Stanford University Headache and Facial Pain Program  Palo Alto California USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2025,11,4]]},"reference":[{"key":"e_1_2_12_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)30925-9"},{"key":"e_1_2_12_3_1","doi-asserted-by":"publisher","DOI":"10.1111\/head.13511"},{"key":"e_1_2_12_4_1","doi-asserted-by":"publisher","DOI":"10.18553\/jmcp.2020.20100"},{"key":"e_1_2_12_5_1","doi-asserted-by":"publisher","DOI":"10.1111\/head.12601"},{"key":"e_1_2_12_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.mayocp.2016.02.013"},{"key":"e_1_2_12_7_1","doi-asserted-by":"publisher","DOI":"10.18553\/jmcp.2020.20103"},{"key":"e_1_2_12_8_1","doi-asserted-by":"publisher","DOI":"10.1111\/head.13456"},{"key":"e_1_2_12_9_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1526-4610.2003.03034.x"},{"key":"e_1_2_12_10_1","doi-asserted-by":"publisher","DOI":"10.1111\/head.13700"},{"key":"e_1_2_12_11_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-2982.2008.01578.x"},{"key":"e_1_2_12_12_1","volume-title":"D.H.E. 45 (dihydroergotamine mesylate) [package insert]","year":"2022"},{"key":"e_1_2_12_13_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1526-4610.2006.00605.x"},{"key":"e_1_2_12_14_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1526-4610.2010.01662.x"},{"key":"e_1_2_12_15_1","doi-asserted-by":"publisher","DOI":"10.1111\/head.13476"},{"key":"e_1_2_12_16_1","volume-title":"Migranal (Dihydroergotamine Mesylate). Prescribing Information","year":"2022"},{"key":"e_1_2_12_17_1","doi-asserted-by":"publisher","DOI":"10.1111\/head.14685"},{"key":"e_1_2_12_18_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40263-024-01118-8"},{"key":"e_1_2_12_19_1","doi-asserted-by":"publisher","DOI":"10.1177\/0333102417738202"},{"key":"e_1_2_12_20_1","doi-asserted-by":"publisher","DOI":"10.1111\/head.14184"},{"key":"e_1_2_12_21_1","unstructured":"ShrewsburySB HoekmanJ JelevaM.Patient acceptability of a novel upper nasal delivery system for DHE mesylate using the POD device \u2013 results from the open\u2010label STOP 301 trial [poster]. Presented at AHS.2020."},{"key":"e_1_2_12_22_1","doi-asserted-by":"publisher","DOI":"10.1097\/WCO.0000000000001267"},{"key":"e_1_2_12_23_1","doi-asserted-by":"publisher","DOI":"10.1111\/head.12499"},{"key":"e_1_2_12_24_1","doi-asserted-by":"publisher","DOI":"10.1111\/head.14067"},{"key":"e_1_2_12_25_1","doi-asserted-by":"publisher","DOI":"10.1111\/head.14153"},{"key":"e_1_2_12_26_1","doi-asserted-by":"publisher","DOI":"10.1111\/head.14430"},{"key":"e_1_2_12_27_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.heliyon.2023.e16187"},{"key":"e_1_2_12_28_1","doi-asserted-by":"publisher","DOI":"10.1111\/head.13588"},{"key":"e_1_2_12_29_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-020-01494-9"}],"container-title":["Headache: The Journal of Head and Face Pain"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/headachejournal.onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/head.15086","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/headachejournal.onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/head.15086","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/headachejournal.onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/head.15086","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T09:56:56Z","timestamp":1773309416000},"score":1,"resource":{"primary":{"URL":"https:\/\/headachejournal.onlinelibrary.wiley.com\/doi\/10.1111\/head.15086"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,4]]},"references-count":28,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["10.1111\/head.15086"],"URL":"https:\/\/doi.org\/10.1111\/head.15086","archive":["Portico"],"relation":{},"ISSN":["0017-8748","1526-4610"],"issn-type":[{"value":"0017-8748","type":"print"},{"value":"1526-4610","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,4]]},"assertion":[{"value":"2024-12-19","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-08-28","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-11-04","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}